WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317192
CAS#: 144-14-9
Description: Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s. It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity. By binding to and activating opioid receptors in the central nervous sytem (CNS), anileridine mimics the endogenous opioids resulting in a decrease of nociceptve neurotransmitters and eventually an analgesic effect. Anileridine is discontinued.
MedKoo Cat#: 317192
Name: Anileridine
CAS#: 144-14-9
Chemical Formula: C22H28N2O2
Exact Mass: 352.21508
Molecular Weight: 352.47
Elemental Analysis: C, 74.97; H, 8.01; N, 7.95; O, 9.08
Anileridine is discontinued. (DEA controlled substance)
Synonym: Apodol; Alidine; Leritin; Leritine; Nipecotan
IUPAC/Chemical Name: ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
InChi Key: LKYQLAWMNBFNJT-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
SMILES Code: CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3
The following data is based on the product molecular weight 352.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Moss JH. Anileridine-induced delirium. J Pain Symptom Manage. 1995 May;10(4):318-20. PubMed PMID: 7541439.
2: Xu YQ, Fang HJ, Xu YX, Duan HJ, Wu Y. [Studies on the analysis of anileridine, levorphanol, nalbuphine and ethamivan in urine]. Yao Xue Xue Bao. 1991;26(8):606-10. Chinese. PubMed PMID: 1805523.
3: Yrjölä H, Heinonen J, Tuominen M, Heikkilä J. Comparison of haemodynamic effects of pethidine and anileridine in anaesthetised patients. Acta Anaesthesiol Scand. 1981 Oct;25(5):412-5. PubMed PMID: 6896113.
4: Ecker RI. Contact dermatitis to anileridine. Contact Dermatitis. 1980 Dec;6(7):495. PubMed PMID: 6894270.
5: Leander JD. Comparison of morphine, meperidine, anileridine, and alphaprodine on schedule-controlled responding and analgesia. Pharmacol Biochem Behav. 1980 May;12(5):797-801. PubMed PMID: 6104822.
6: Leander JD. Comparing the effects of anileridine, alphaprodine and fentanyl on schedule-controlled responding by pigeons. J Pharmacol Exp Ther. 1978 Sep;206(3):624-35. PubMed PMID: 581295.
7: Dykstra LA, Leander JD. Electric shock titration: effects of meperidine, anileridine and alphaprodine. Pharmacol Biochem Behav. 1978 Apr;8(4):387-9. PubMed PMID: 97674.
8: Freeman DS, Gjika HB, Van Vunakis H. Radioimmunoassay for normeperidine: studies on the N-dealkylation of meperidine and anileridine. J Pharmacol Exp Ther. 1977 Oct;203(1):203-12. PubMed PMID: 578528.
9: Tuominen M. Comparison of anileridine and pethidine in patients with pain following upper abdominal surgery. Ann Chir Gynaecol. 1976;65(3):207-15. PubMed PMID: 786135.
10: Tuominen M. Comparison of the effect of anileridine and pethidine on the intracholedochal pressure during constant fluid perfusion. Acta Anaesthesiol Scand. 1976;20(2):177-82. PubMed PMID: 779392.
